Genzyme boosts AnorMED bid to $580M

Genzyme has announced it is willing to offer $13.50 a share for AnorMED in a deal valued at $580 million. That's $200 million more than it offered a few weeks ago and $65 million higher than the offer from Millennium Pharmaceuticals, which AnorMED has recommended to investors. Genzyme's seriously sweetened offer is contingent on AnorMED's support. AnorMED's board swiftly rejected Genzyme's original offer in September, noting that it felt the $8.55 bid significantly undervalued the company. In the new proposal, Genzyme is also looking to do more due diligence on Mozobil, AnorMED's lead product.

- read the AFX report for more information

Suggested Articles

The patient was hospitalized with febrile neutropenia in the weeks after receiving the drug and died 52 days post-treatment with the CAR-T therapy.

The trial has been paused since early September while FDA reviews the safety of the vaccine in light of a reported case of an inflammatory disorder.

Biogen is cutting its experimental multiple sclerosis drug opicinumab as well as an spinal muscular atrophy candidate amid a third-quarter clear-out.